Anti-GBM Antibody Disease Medication

Updated: Jun 06, 2022
  • Author: Agnieszka Swiatecka-Urban, MD, FASN, FAAP; Chief Editor: Craig B Langman, MD  more...
  • Print

Medication Summary

The treatment of choice is a combination of plasmapheresis to remove circulating anti-glomerular basement membrane (GBM) antibodies and immunosuppression with glucocorticoids and cytotoxic agents to inhibit further autoantibody formation.



Class Summary

These agents are used as adjuncts to plasmapheresis to minimize antibody formation. Glucocorticoids have anti-inflammatory properties and cause profound and varied metabolic effects. They modify the body's immune response to diverse stimuli.

Methylprednisolone (Medrol, Solu-Medrol)

DOC. Should be started concomitantly with plasmapheresis.

Prednisone (Deltasone, Orasone, Liquid Pred)

Administer after methylprednisolone pulses and continue for 6-12 mo, depending on response and adverse effects.


Immunosuppressive agents

Class Summary

Immunosuppressants are used as adjuncts to plasmapheresis and glucocorticoids to minimize new antibody formation. Therapy is continued for 6-12 months, the time usually required to stop the formation of anti-GBM antibodies.

Cyclophosphamide (Cytoxan, Neosar)

DOC because of long-standing use in adults and children.